Molecular Partners AG

Molecular Partners AG (MOLN) priced its initial public offering on Jun 16, 2021 at $21.25 per ADS, raising $63.8M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $683.4M. J.P. Morgan was lead-left underwriter, joined by Leerink Partners, TD Cowen and RBC Capital Markets. Cooley advised the company and Davis Polk advised the underwriters.

Molecular Partners AG is a clinical-stage biopharmaceutical company developing DARPin protein therapeutics, with a current focus on infectious disease, oncology and ophthalmology. DARPins are designed from ankyrin repeat proteins and can be built with multiple mechanisms of action.

Status

IPO

Ticker

MOLN

Exchange

Nasdaq Global Select

Priced

Jun 16, 2021

IPO price

$21.25 per ADS

Raised

$63.8M

Market cap at IPO price

$683.4M

First filed

Apr 22, 2021

Underwriters

J.P. Morgan, Leerink Partners, TD Cowen and RBC Capital Markets

Company counsel

Cooley

Underwriters' counsel

Davis Polk

Sector

Biotech & pharma

Country / state

Switzerland

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.